Compare Sanofi SA (SNY) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Western Union Co — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while Western Union Co trades at $8.9 (market cap $2.71B). The key difference: Sanofi SA is far larger — about 38.7× Western Union Co's market cap, and Western Union Co pays the higher dividend (10.85%). Which is the better fit depends on your goals.
| SNY | WU | |
|---|---|---|
Market Cap | $104.83B | $2.71B |
Sector | Health | Technology |
52-Week High | $52.34 | $10.28 |
52-Week Low | $41.33 | $7.04 |
Enterprise Value | $121.32B | $2.40B |
Dividend Yield | 5.5% | 10.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Western Union (WU) trades at $8.46, down 4.73% on the day, with a bullish technical signal but mixed sentiment. The stock shows attractive valuation metrics with a P/E of 6.37 and P/S of 0.69, supported by strong profitability including a 10.88% net margin and 47.66% ROE. Recent developments include a partnership with Total Wireless and pending acquisition of Intermex, while Q1 2026 earnings missed expectations. Cash flow trends show volatility, with 2025 net cash flow negative $469.2 million.
Outlook remains cautious due to declining revenue trends and mixed analyst ratings, with 58% hold recommendations. The 11% dividend yield offers income appeal, but competitive pressures and execution risks on digital transformation pose challenges. Near-term catalyst is Q2 2026 results on July 30, 2026, with consensus EPS estimate of $0.43.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
